Erschienen in:
01.12.2001 | Paper Report
Neuropeptide treatment inhibits arthritis
verfasst von:
Cheryl Smythe
Erschienen in:
Arthritis Research & Therapy
|
Ausgabe 1/2000
Einloggen, um Zugang zu erhalten
Excerpt
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 38 amino acid neuropeptide belonging to the secretin-glucagon vasoactive intestinal peptide (VIP) family, which exhibits anti-inflammatory properties. PACAP has been shown to protect mice from lethal endotoxemia by decreasing proinflammatory cytokines and increasing anti-inflammatory cytokines. Furthermore, PACAP stimulates a Th2 response. Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which the imbalance in inflammatory cytokines and T-cell responses play a key role. The authors therefore propose that PACAP may be effective in treating both the inflammatory and autoimmune conditions of RA and investigate this in an animal model of collagen-induced arthritis (CIA). …